Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05825066Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2023
- Primary completion
- Jun 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paclitaxel, mFOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by Wake Forest University Health Sciences. Started Aug 2023; status: recruiting.
02
Drugs
gemcitabinepaclitaxelmFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05825066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05825066.